Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Jon Pilcher, chief executive officer at Neuren Pharmaceuticals (ASX:NEU).

Neuren is developing new therapies for neurodevelopmental disorders with high unmet need.

The company was covered in a recent Stockhead article, following news of it beginning the phase 1 trial of its potential treatment for three rare neurodevelopmental disorders. 

So tune in below to hear about all things Neuren.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!

Read MoreDrug DevelopmentHealth

Featured Companies

You might be interested in